| Bhupesh Rathod, MD | |
|
1455 Battersby Ave, Enumclaw, WA 98022 | |
| (253) 426-6341 | |
| (253) 426-6344 |
| Full Name | Bhupesh Rathod |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 18 Years |
| Location | 1455 Battersby Ave, Enumclaw, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699077263 | NPI | - | NPPES |
| 7100167000 | Medicaid | KY | |
| 201023160 | Medicaid | IN | |
| 2029557 | Medicaid | WA | |
| 3149060 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 35-097132 (Ohio) | Secondary |
| 208M00000X | Hospitalist | 35-097132 (Ohio) | Secondary |
| 208M00000X | Hospitalist | MD60332000 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Medical Center | Tacoma, WA | Hospital |
| St Francis Community Hospital | Federal way, WA | Hospital |
| Highline Medical Center | Burien, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
Spectranetics Corporation today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg.
While the warm summer months are perfect for spending time outside, several environmental factors can spell trouble for eyesight. One University of Alabama at Birmingham optometrist says knowledge of what to do, and what not to do, will keep eyes healthy.
Viking Systems, Inc. announced today that it will present its Next Generation 3DHD technology at the 5th International Symposium on Hybrid Approach to Congenital Heart Disease (ISHAC) from August 31 - September 2, 2010 in Columbus, Ohio.
Current post-operative pain control methods have proved inadequate for those who have undergone total knee replacement (TKR), according to University of Iowa College of Nursing researcher.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 6 days ago
| Entity Name | South Sound Inpatient Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023285756 PECOS PAC ID: 5991618738 Enrollment ID: O20031107000668 |
News Archive
Spectranetics Corporation today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg.
While the warm summer months are perfect for spending time outside, several environmental factors can spell trouble for eyesight. One University of Alabama at Birmingham optometrist says knowledge of what to do, and what not to do, will keep eyes healthy.
Viking Systems, Inc. announced today that it will present its Next Generation 3DHD technology at the 5th International Symposium on Hybrid Approach to Congenital Heart Disease (ISHAC) from August 31 - September 2, 2010 in Columbus, Ohio.
Current post-operative pain control methods have proved inadequate for those who have undergone total knee replacement (TKR), according to University of Iowa College of Nursing researcher.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 6 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
Spectranetics Corporation today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg.
While the warm summer months are perfect for spending time outside, several environmental factors can spell trouble for eyesight. One University of Alabama at Birmingham optometrist says knowledge of what to do, and what not to do, will keep eyes healthy.
Viking Systems, Inc. announced today that it will present its Next Generation 3DHD technology at the 5th International Symposium on Hybrid Approach to Congenital Heart Disease (ISHAC) from August 31 - September 2, 2010 in Columbus, Ohio.
Current post-operative pain control methods have proved inadequate for those who have undergone total knee replacement (TKR), according to University of Iowa College of Nursing researcher.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 6 days ago
| Entity Name | Cogent Healthcare Of Washington, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861430522 PECOS PAC ID: 2062306350 Enrollment ID: O20040209000839 |
News Archive
Spectranetics Corporation today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg.
While the warm summer months are perfect for spending time outside, several environmental factors can spell trouble for eyesight. One University of Alabama at Birmingham optometrist says knowledge of what to do, and what not to do, will keep eyes healthy.
Viking Systems, Inc. announced today that it will present its Next Generation 3DHD technology at the 5th International Symposium on Hybrid Approach to Congenital Heart Disease (ISHAC) from August 31 - September 2, 2010 in Columbus, Ohio.
Current post-operative pain control methods have proved inadequate for those who have undergone total knee replacement (TKR), according to University of Iowa College of Nursing researcher.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 6 days ago
| Entity Name | Grant County Public Hospital District 1 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619086766 PECOS PAC ID: 9931095692 Enrollment ID: O20040227000602 |
News Archive
Spectranetics Corporation today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg.
While the warm summer months are perfect for spending time outside, several environmental factors can spell trouble for eyesight. One University of Alabama at Birmingham optometrist says knowledge of what to do, and what not to do, will keep eyes healthy.
Viking Systems, Inc. announced today that it will present its Next Generation 3DHD technology at the 5th International Symposium on Hybrid Approach to Congenital Heart Disease (ISHAC) from August 31 - September 2, 2010 in Columbus, Ohio.
Current post-operative pain control methods have proved inadequate for those who have undergone total knee replacement (TKR), according to University of Iowa College of Nursing researcher.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bhupesh Rathod, MD Po Box 31001-1518, Pasadena, CA 91110-1518 Ph: (253) 779-6260 | Bhupesh Rathod, MD 1455 Battersby Ave, Enumclaw, WA 98022 Ph: (253) 426-6341 |
News Archive
Spectranetics Corporation today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg.
While the warm summer months are perfect for spending time outside, several environmental factors can spell trouble for eyesight. One University of Alabama at Birmingham optometrist says knowledge of what to do, and what not to do, will keep eyes healthy.
Viking Systems, Inc. announced today that it will present its Next Generation 3DHD technology at the 5th International Symposium on Hybrid Approach to Congenital Heart Disease (ISHAC) from August 31 - September 2, 2010 in Columbus, Ohio.
Current post-operative pain control methods have proved inadequate for those who have undergone total knee replacement (TKR), according to University of Iowa College of Nursing researcher.
Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.
› Verified 6 days ago